Development of Phenoxyacetic Acid Hybrids With COX‐2 Inhibitory Activity as Potential Anti‐Neuroinflammatory Agents
Drug Development Research · 2026
DOI: 10.1002/ddr.70363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Mohammad H Alqarni und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacognosy, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia. Hauptthemen laut MEDLINE: Cyclooxygenase 2 Inhibitors, Acetates, Anticonvulsants, Ethylene Glycols. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Prince Sattam bin Abdulaziz University.
Abstract (Originalsprache)
This research employs a molecular hybridization strategy to repurpose the pyrazoline scaffold 6a, 6c, 7a‐c, 11a, and 12b , transforming it into a high‐efficiency conjugate designed to tackle the multifaceted pathology of neuroinflammation and epilepsy. By integrating a selective phenoxyacetic acid moiety. Our findings identified compound 7c as a potential lead candidate for the development of novel anticonvulsant agents. In vivo trials demonstrated that 7c offers a superior therapeutic window compared to valproic acid, yielding 90% seizure protection in PTZ models and a remarkable 212.27% delay in seizure onset within the pilocarpine model, alongside 100% survival. Beyond mere symptomatic suppression, 7c re‐engineers the hippocampal environment by slashing glutamate‐driven excitotoxicity by 64.23% and silencing the cytokine‐glial activation axis (TNF‐alpha, IL‐6, GFAP, and Iba‐1). Supported by ADME profile confirming optimal BBB permeability and molecular docking indicating a robust binding affinity of −10.3 kcal/mol, this study positions 7c as a versatile, non‐toxic, and repurposed‐ready hybrid candidate for advanced neuroprotective intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacognosy, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia.
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Egyptian-Russian University, Badr City, Cairo, Egypt.
- Department of Biochemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, Egypt.
- Applied Organic Chemistry Department, National Research Center, Dokki, Cairo, Egypt.
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, Egypt.
ORCID-Profile: Mohammad H Alqarni, Mahmoud Abdelrahman Alkabbani, Aya Mohamed Ahmed Ibrahim, Ahmed I Foudah, Tariq M Aljarba, Hatem A Abdel-Aziz, Mohamed K Elgohary
Förderung
- Prince Sattam bin Abdulaziz University
Zitieren
APA
Alqarni, M. H., Alkabbani, M. A., Ibrahim, A. M. A., Foudah, A. I., Aljarba, T. M., Alam, A., Abdel-Aziz, H. A., & Elgohary, M. K. (2026). Development of Phenoxyacetic Acid Hybrids With COX‐2 Inhibitory Activity as Potential Anti‐Neuroinflammatory Agents. Drug Development Research. https://doi.org/10.1002/ddr.70363
Vancouver
Alqarni MH, Alkabbani MA, Ibrahim AMA, Foudah AI, Aljarba TM, Alam A, et al. Development of Phenoxyacetic Acid Hybrids With COX‐2 Inhibitory Activity as Potential Anti‐Neuroinflammatory Agents. Drug Development Research. 2026. doi:10.1002/ddr.70363
BibTeX
@article{Alqarni2026,
author = {Alqarni, Mohammad H and Alkabbani, Mahmoud Abdelrahman and Ibrahim, Aya Mohamed Ahmed and Foudah, Ahmed I and Aljarba, Tariq M and Alam, Aftab and Abdel-Aziz, Hatem A and Elgohary, Mohamed K},
title = {Development of Phenoxyacetic Acid Hybrids With COX‐2 Inhibitory Activity as Potential Anti‐Neuroinflammatory Agents},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70363}
}
EUVIMED